摘要
目的探讨晚期非小细胞肺癌(NSCLC)不同化疗方案的临床疗效和经济学效果。方法将178例晚期NSCLC患者随机分为EP组(依托泊苷注射液+注射用顺铂)、NP组(酒石酸长春瑞宾注射液+注射用顺铂)、GP组(盐酸吉西他滨注射液+注射用顺铂)3组,运用药物经济学成本-效果分析方法,对3种化疗方案进行分析和评价。结果EP,NP,GP方案的有效率分别为38.9%,46.5%,56.6%,一个疗程的化疗费用分别为11930.60元、42684.25元、44195.87元。在EP方案的基础上,每增加一个单位效果,NP方案、GP方案所需追加的成本分别为4046.53元、1822.90元。结论GP方案为晚期NSCLC的较好治疗方案。
Objective To investigate the economic effects of three chemotherapy schemes in the treatment of non-small cell lung cancer （NSCLC）. Methods 178 cases of advanced NSCLC were randomly divided into 3 groups, group EP, group NP and group GP. The cost effectiveness of the 3 groups were compared using pharmaceutical economics. Results 3 schemes costed 11 930. 60 yuan, 42 684. 25 yuan and 44 195.87 yuan respectively. The effective rates were 38.9%, 46. 5% and 56.6% respectively. On the basis of scheme EP, scheme NP and GP increased the cost of g 046.53 yuan and 1 822.90 yuan respectively. Conclusion Scheme GP is the preferable choice.
出处
《中国药业》
CAS
2007年第7期29-30,共2页
China Pharmaceuticals
关键词
非小细胞肺癌
化疗方案
成本-效果分析
药物经济学
non- small cell lung cancer
chemotherapy scheme
cost- effectiveness analysis
pharmaceutical economics
